A detailed history of Ci Investments Inc. transactions in Incyte Corp stock. As of the latest transaction made, Ci Investments Inc. holds 5,901 shares of INCY stock, worth $406,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,901
Previous 6,516 9.44%
Holding current value
$406,224
Previous $395,000 1.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$57.33 - $68.61 $35,257 - $42,195
-615 Reduced 9.44%
5,901 $390,000
Q2 2024

Aug 12, 2024

BUY
$51.18 - $63.75 $8,086 - $10,072
158 Added 2.49%
6,516 $395,000
Q1 2024

May 13, 2024

BUY
$56.55 - $66.59 $131,026 - $154,289
2,317 Added 57.34%
6,358 $362,000
Q4 2023

Feb 12, 2024

BUY
$52.16 - $64.19 $21,229 - $26,125
407 Added 11.2%
4,041 $254,000
Q3 2023

Nov 13, 2023

SELL
$57.77 - $65.93 $29,636 - $33,822
-513 Reduced 12.37%
3,634 $210,000
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $124,764 - $154,568
2,047 Added 97.48%
4,147 $258,000
Q1 2023

May 12, 2023

BUY
$70.23 - $86.01 $92,773 - $113,619
1,321 Added 169.58%
2,100 $152,000
Q4 2022

Feb 10, 2023

BUY
$67.18 - $84.11 $18,272 - $22,877
272 Added 53.65%
779 $63,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $14,559 - $18,229
220 Added 76.66%
507 $34,000
Q2 2022

Aug 12, 2022

SELL
$66.18 - $83.18 $43,678 - $54,898
-660 Reduced 69.69%
287 $22,000
Q1 2022

May 12, 2022

SELL
$66.02 - $79.71 $4,489 - $5,420
-68 Reduced 6.7%
947 $75,000
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $12,161 - $14,229
192 Added 23.33%
1,015 $75,000
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $56,515 - $69,148
823 New
823 $57,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Ci Investments Inc. Portfolio

Follow Ci Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.